Avalon GloboCare (NASDAQ:ALBT) Trading Up 1.4% – Time to Buy?

Shares of Avalon GloboCare Corp. (NASDAQ:ALBT) rose 1.4% on Friday . The company traded as high as $0.37 and last traded at $0.3571. Approximately 116,661 shares were traded during trading, a decline of 58% from the average daily volume of 274,666 shares. The stock had previously closed at $0.3520.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Avalon GloboCare Price Performance

The business has a 50 day moving average of $0.42 and a 200 day moving average of $0.82. The firm has a market capitalization of $4.30 million, a price-to-earnings ratio of -0.10 and a beta of -0.06.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings data on Monday, March 30th. The company reported $0.46 EPS for the quarter.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.